Argentina: Compulsory License On Imatinib Mesylate – Drug Determined To Be Of Public Interest By The Colombian Government

Last Updated: 21 September 2016
Article by Miriam Silvestri


The Colombian Ministry of Health, through its Minister Alejandro Gaviria, seeks to declare the drug product Glivec® of public interest, meaning it would improve the well-being of the general population  The product is used to treat Leukemia,its active ingredient being polymorph β of Imatinib mesylate and is currently marketed by Novartis, holder of exclusive rights the drug. This is the first step for the Colombian Superintendence of Industry and Commerce to declare the compulsory license for the production of the drug product by generic laboratories, which would allow the commercialization of the drug product at a lower price.

Novartis holds the invention patent No. 29270, called «Crystal Modification Of a N-Phenyl-2-Pyrimidineamine Derivative, Processes for its Manufacture and its Use», granted by the Superintendence of Industry and Commerce through Resolution No. 24250 of April 25, 2012, in force until July 9, 2018.

The patent claims the polymorphic form β of the compound Imatinib mesylate and it is intended for the treatment of all the stages of Philadelphia chromosome-positive leukemia and Chronic Myeloid Leukemia (Ph+ CML), metastasis and/or KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST), as well as other types of cancer).  Patients receiving Glivec® show a survival rate of 90% and can often achieve a long and productive life. To the contrary, patients who are not treated with Glivec® show a life expectancy of only 30%.

The patent application was filed before the Colombian Superintendence of Industry and Commerce on July 9, 1998. In 2003, after the examination process, the application was rejected for non-compliance with the patentability requirements of novelty and inventive step, pursuant to Decision 486. The resolution of denial allowed Colombian laboratories to manufacture and commercialize the generic products of the same molecule for several years. Novartis appealed the decision before the State Council: the company obtained a favorable ruling and the patent was finally granted in 2012. As a consequence, the domestic laboratories were forced to withdraw their generics out of the market and they had no choice but to negotiate a patent license with Novartis.

According to Colombian Ministry of Health, the granting of the patent resulted in a significant growth of the costs of public health regarding the treatment of leukemia. The Ministry tried to set the price of Glivec® at 140 Colombian pesos (equivalent to USD 0.05) per mg, (less than 50% of the annual USD 15,000 that the Government spends per treatment per patient) –but Novartis rejected the proposal.

This decision boosted the Ministry of Health to declare the molecule Imatinib (Glivec®) of public interest; and, for the first time in Colombia, a compulsory license would force Novartis to negotiate the price of this product with other laboratories.

The Ministry argues the existence of a growing pressure on the health budget requires putting an end to Novartis' control on Imatinib supply and the issuing of a compulsory license as an exception to a patent when deemed a matter of public interest.

The imposition of a compulsory license, however, would not lead to similar measures for other drug products as this is a legal but exceptional decision, according to the Ministry.

Glivec® was Novartis' most sold product last year, generating incomes of USD 4,700 billion. Sales drop dramatically after a cheaper generic version was launched into the US market in February.

The debate over Imatinib could set a precedent for other countries facing rising drug prices.


Novartis opposes a declaration of public interest. The company argues that there is no legitimate basis for the Ministry of Health to issue a compulsory license on Imatinib patent. This position is founded on the following grounds:

  • 1. The patent in question has been legitimately granted for the crystal form of Imatinib mesylate, marketed in Colombia as Glivec®.
  • 2. Sanitary records for Novartis Glivec are in force.
  • 3. There are already other four pharmaceutical companies on the market that commercialize Imatinib and do not infringe Novartis' patent. In the INVIMA [Colombian National Institute for Medicine and Food Surveillance] there are 19 sanitary records of new drug products pending approval.
  • 4. The existence of Glivec® patent does not affect patients' access to treatment. The molecule is part of the treatment of Chronic Myeloid Leukemia included in the Colombian Compulsory Health Plan (POS).
  • 5. Glivec® price has been set and controlled since 2011 by the National Government.
  • 6. A public interest declaration on Glivec® does not represent a solution to the financial challenges faced by the Colombian healthcare system.
  • 7. There is no threat of Imatinib shortage: Novartis has always guaranteed adequate and uninterrupted access to the treatment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions